IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label generic drug. Show all posts
Showing posts with label generic drug. Show all posts
Thursday, 12 January 2017

When a company's future is caught in the generic drug/proprietary drug crosshairs

›
There is nothing in any other IP regime analogous to the generic/proprietary divide with respect to the exploitation of patent rights in ...
1 comment:
›
Home
View web version
Powered by Blogger.